Read the Registration Document - Guerbet

More documents

Recommendations

Info

3) Societal informationa) Territorial, economic and social impactAs an economic stakeholder in the regions where it operates, Guerbet is committed to modernising itsindustrial infrastructure and developing more ecological solutions. With this objective, €197 million wereinvested from 2005 to 2012 at the French sites of Aulnay (Seine-Saint-Denis), Lanester (Morbihan), Marans(Charente Maritime) and Gonesse (Val d’Oise). The employment generated from these activities is thuslargely local and regional.b) Relations with stakeholdersGuerbet supports different organisations and associations concerned by the development and activity of theGroup. Areas covered concern measures in favour of integration, general education and organisationshaving a connection with Guerbet's activities (for example, medical and pharmacy schools).The partnership with the association "Nos quartiers ont du talent" was in this way strengthened in 2012.This mentoring programme for young students from under-resourced urban districts engaged in a jobsearch enabled Guerbet employees to contribute their advice on CVs, letters of motivation or recruitmentinterviews.As for the Lanester site, it opened up its doors to young students from the Lorient University Institute ofTechnology (IUT) to provide them with an opportunity to discover the company, the different business linesand the requirements for a production site of active pharmaceutical ingredients.The Marans and Lanester sites, through local coordinating bodies (CLIC or Comité Local d’Information etde Concertation), engage with stakeholders that include residents from neighbouring areas, regionalgovernments and representatives of the central government, on the report evaluating their operatingactivity. In 2012, the status of the review of the PPRT technology risk prevention plans was presented.c) Subcontracting, suppliers and fair practicesThe Group's financial and purchasing policies establish in particular rules for ethical conduct in relationswith Guerbet's partners (suppliers, subcontractors, etc.). The Group is also subject to strict regulationsgoverning relations with professionals in the healthcare sector (for example, French DMOS act regulatingrelations between businesses and the medical profession).In 2012, Guerbet continued to participate in the CSR (Corporate Social Responsibility) committee of LEEM(1) . These exchanges provided an opportunity to share sector-based good practices and raise awareness ofinternal teams about the issue of "Responsible Purchasing".(1)"Les Entreprises du Médicament" – the French Pharmaceutical Companies Association69
FINANCIAL STATEMENTS AND NOTES1) Consolidated financial statements and notesASSETS (net)a) Guerbet Group consolidated financial statementsIn thousands of euros• Consolidated balance sheetNote 2012 2011Intangible assets 5 36,254 35,772Property, plant and equipment 6 189,582 183,141Non-current financial assets 7 3,200 7,590Deferred tax liabilities 8 9,250 10,896Total non-current assets 238,286 237,399Inventories 9 105,146 104,495Trade receivables and related accounts 10 & 1.1 86,826 85,254Current assets held for sale - -Other current financial assets 1.1 20,235 14,699Cash and cash equivalents 1.2 10,473 7,872Total current assets 222,680 212,320TOTAL ASSETS 460,966 449,719LIABILITIES AND EQUITY (net)In thousands of eurosNote 2012 2011Share capital 12,200 12,200Other reserves 192,407 185,023Consolidated net income 20,399 14,427Currency translation adjustments 1,203 3,148Shareholders' equityof which attributable to equity holders of the parentcompany11 226,209226,209214,798214,798Non-current financial liabilities 2.1 67,043 79,518Other non-current financial liabilities 2.0 2,258 1,529Deferred tax liabilities 8 10,345 8,603Provisions 12 20,927 16,871Total non-current liabilities 100,573 106,521Trade payables and equivalent 38,855 48,409Current financial liabilities 2.1 42,439 28,393Other current financial liabilities 2.6 42,429 40,642Current tax liabilities 6,436 5,781Provisions 12 4,025 5,175Total current liabilities 134,184 128,400TOTAL EQUITY AND LIABILITIES 460,966 449,71970
Page 3 and 4:
CONTENTSCHIEF EXECUTIVE OFFICERS’
Page 5 and 6:
CHIEF EXECUTIVE OFFICERS’ MESSAGE
Page 7 and 8:
THE GUERBET GROUP1) History of the
Page 9 and 10:
3) Business overview3.1 Guerbet is
Page 11 and 12:
3.4 The pathologiesIn Oncology, the
Page 13:
Guerbet's offering of products is c
Page 16 and 17:
c) Research & development• R&D ob
Page 18 and 19:
• A proactive partnering strategy
Page 20 and 21: 5) Group organisation at 31 Decembe
Page 22 and 23: e) DistributionGuerbet distribute i
Page 24 and 25: DirectorsOther offices and director
Page 26 and 27: There exist no arrangements or unde
Page 28 and 29: Summary of compensation for Marie-C
Page 30 and 31: • Stock options granted to non-of
Page 32 and 33: I - 1Organisation of the work of th
Page 34 and 35: "Research and Innovation" Committee
Page 36 and 37: II - Internal control and risk mana
Page 38 and 39: 4) Statutory Auditors’ report pre
Page 40 and 41: SHAREHOLDER INFORMATION1) The Guerb
Page 42 and 43: As at 31 December 2010SHARESVOTING
Page 44 and 45: considered to have automatically re
Page 46 and 47: 10) Provisions of the Articles of A
Page 48 and 49: c) Earnings highlightsIFRS(in thous
Page 50 and 51: g) OutlookStrongly focused on the n
Page 52 and 53: 3) Risk factorsThe company conducte
Page 54 and 55: • Sourcing risksGuerbet has an ex
Page 56 and 57: • Information technology risksAn
Page 58 and 59: • Five-year summary of consolidat
Page 60 and 61: • Other information included in t
Page 62 and 63: • Recruitment and dismissalsGuerb
Page 64 and 65: and employee savings. The goal is s
Page 66 and 67: • Measures adopted to promote emp
Page 68 and 69: ) Pollution and waste managementThe
Page 72 and 73: • Consolidated income statementIn
Page 74 and 75: In thousands of euros• Statement
Page 76 and 77: Changes in standards and interpreta
Page 78 and 79: g) Research and development expendi
Page 80 and 81: Held to maturity investmentsHeld-to
Page 82 and 83: creation are recorded under "Other
Page 84 and 85: III) Notes to the financial stateme
Page 86 and 87: Aged trial balance information for
Page 88 and 89: 2.2 - Borrowings by currencyCurrenc
Page 90 and 91: 3.3 - Analysis of the sensitivity o
Page 92 and 93: Revenue2012European companiesfor th
Page 94 and 95: In 2005, the Group acquired for ¥5
Page 96 and 97: 6.2 - Analysis of property, plant a
Page 98 and 99: The change in the net value of inve
Page 100 and 101: 12.2 - Accrued employee benefitsa)
Page 102 and 103: Change in net liabilities of the pe
Page 104 and 105: 14.4 - Personnel by region at year-
Page 106 and 107: Note 22 - Research and development
Page 108 and 109: Note 25 - Related parties25.1 - Rel
Page 110 and 111: Note 27 - Basic earnings per share
Page 112 and 113: 2) Auditors’ report on the consol
Page 114 and 115: 3) Parent company financial stateme
Page 116 and 117: • Income statementIn thousands of
Page 118 and 119: • Statement of cash flowsIn milli
Page 120 and 121:
c) Property, plant and equipmentPro
Page 122 and 123:
Note 1 - Intangible assets1 - 1 - C
Page 124 and 125:
Note 6 - Receivables by maturityCos
Page 126 and 127:
Note 9 - Regulated provisionsInvest
Page 128 and 129:
Note 13 - Sales by region2012 2011F
Page 130 and 131:
Tax income or expense recorded in t
Page 132 and 133:
Debt waiver agreements granted to a
Page 134 and 135:
Capital lease commitments relative
Page 136 and 137:
4) Auditors' report on the separate
Page 138 and 139:
5) Auditors' special report on rela
Page 140 and 141:
ORDINARY AND EXTRAORDINARY GENERAL
Page 142 and 143:
RESOLUTION THREE (Special report of
Page 144 and 145:
Extraordinary resolutionsRESOLUTION
Page 146 and 147:
3) Report of the Board of Directors
Page 148 and 149:
Application of legal provisions gov
Page 150 and 151:
• Tenth draft resolution: stock s
Page 152 and 153:
2) The Statutory Auditorsa) Statuto
Page 154 and 155:
6) Articles of association (selecte
Page 156 and 157:
7) 2013 shareholders calendarEventD
Page 158 and 159:
) Annual financial reportInformatio
show all

Read the Registration Document - Guerbet

Create successful ePaper yourself

Delete template?

Save as template?